Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01115790 · ClinicalTrials.gov registry record · Phase 1

A Phase 1 Study in Participants With Advanced Cancer

A Phase 1 study of Carcinoma, Non-Small Cell Lung and Advanced Cancer, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 1
Development phase
150
Enrollment target
5
Study locations

NCT01115790 is a Phase 1 study of Carcinoma, Non-Small Cell Lung and Advanced Cancer that has completed, run by Eli Lilly and Company. The registered enrollment target is 150 participants, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (54% lower). The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01115790, a Phase 1 study of Carcinoma, Non-Small Cell Lung and Advanced Cancer, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 1
Development phase
150 participants
Enrollment target
5
Study locations

Study Summary

The primary purpose of Parts A and B of this study is to evaluate the safety and toxicity of prexasertib (an inhibitor of checkpoint kinase 1\[chk 1\]) in participants with advanced or metastatic cancer (Part A), or squamous cell cancer of the head and neck or squamous cell cancer of any tumor type (Part B). Part C of the study will evaluate prexasertib in three different groups of participants; those with squamous cell cancer of the head and neck that has recurred or spread to other parts of the body, those with squamous non-small cell lung cancer that has recurred or spread, and those with squamous cell cancer of the anus that is not curable by existing therapy.

Conditions Studied

Carcinoma, Non-Small Cell Lung Advanced Cancer Squamous Cell Carcinoma Anal Squamous Cell Carcinoma Carcinoma, Squamous Cell of Head and Neck Lung Squamous Cell Carcinoma Stage IV

Interventions

  • DRUG Prexasertib

Study Locations (5)

Tennessee

  • Sarah Cannon Research Institute SCRI - Nashville
  • Tennessee Oncology PLLC - Nashville

Florida

  • Florida Cancer Specialists - Sarasota

Oklahoma

  • Peggy and Charles Stephenson Oklahoma Cancer Center - Oklahoma City

Texas

  • University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2010-02
Est. Completion 2016-01
Phase Phase 1

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01115790

The ClinicalTrials.gov registry entry for NCT01115790 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (54% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 1 intervention - of which Prexasertib is the first listed.

NCT01115790 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Tennessee, Florida, Oklahoma.

Frequently Asked Questions

What is clinical trial NCT01115790 about?

NCT01115790 is a clinical study titled "A Phase 1 Study in Participants With Advanced Cancer". The primary purpose of Parts A and B of this study is to evaluate the safety and toxicity of prexasertib (an inhibitor of checkpoint kinase 1\[chk 1\]) in participants with advanced or metastatic cancer (Part A), or squamous cell cancer of the head and neck or squamous cell cancer of any tumor type ...

What is the current status of trial NCT01115790?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2010-02. Estimated completion is 2016-01.

What conditions does trial NCT01115790 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Advanced Cancer, Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Carcinoma, Squamous Cell of Head and Neck.

What interventions are being tested in trial NCT01115790?

The interventions under investigation include: Prexasertib (DRUG).

Who is sponsoring clinical trial NCT01115790?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01115790 being conducted?

This trial has 5 study locations across Florida, Oklahoma, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

Advanced Cancer

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.